Revolution Medicines

Yahoo Finance • 2 days ago

Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase

On May 15, 2026, Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals(NASDAQ:CRVS), acquiring 1,100,000 shares in the first quarter for an estimated $17.55 million based on quarterly average pricing. What happened... Full story

Yahoo Finance • 2 days ago

Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally

Boxer Capital Management increased its stake in Kodiak Sciences(NASDAQ:KOD) during the first quarter, adding 225,000 shares in a transaction estimated at $5.81 million based on quarterly average pricing, according to a May 15, 2026, SEC fi... Full story

Yahoo Finance • 2 days ago

Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares

On May 15, 2026, Boxer Capital Management disclosed a purchase of 1,241,000 Vir Biotechnology(NASDAQ:VIR) shares, an estimated $9.89 million trade based on quarterly average pricing. What happened According to a Securities and Exchange C... Full story

Yahoo Finance • 8 days ago

Small-Cap ETF Showdown: Schwab's SCHA vs. iShares' IJR

The Schwab U.S. Small-Cap ETF(NYSEMKT:SCHA) offers lower costs and broader market coverage, while the iShares Core S&P Small-Cap ETF(NYSEMKT:IJR) provides a more concentrated portfolio with higher liquidity. Both funds serve as low-cost g... Full story

Yahoo Finance • 9 days ago

Revolution Medicines (RVMD) Receives FDA’s “Safe to Proceed” Letter for Daraxonrasib

Revolution Medicines, Inc. (NASDAQ:RVMD) is one of the best performing healthcare stocks so far in 2026. Revolution Medicines, Inc. (NASDAQ:RVMD) announced on May 1 that the U.S. Food and Drug Administration (FDA) issued a “safe to proceed... Full story

Yahoo Finance • 13 days ago

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentationRASolute 302 data planned fo... Full story

Yahoo Finance • 16 days ago

Is Teva Pharmaceutical Industries Limited (TEVA) A Good Stock To Buy Now?

Is TEVA a good stock to buy? We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical Industries... Full story

Yahoo Finance • 17 days ago

Revolution Medicines, Inc. (RVMD) One of the Best Stocks to Buy in a Rising Market amid $14B Opportunity

Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 27, shares of Erasca dropped sharply after Revolution Medicines Inc. (NASDAQ:RVMD) accused the company... Full story

Yahoo Finance • 17 days ago

Revolution Medicines Inc. (RVMD): Billionaire Tom Steyer Remains Bullish on This Stock

We just covered Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and Revolution Medicines, Inc. (NASDAQ:RVMD) ranks 5th on this list. Revolution Medicines, Inc. (NASDAQ:RVMD) has featured in the 13F portfolio of Farallon... Full story

Yahoo Finance • 20 days ago

Vanguard vs. Schwab: Which Small-Cap ETF Belongs in Your Portfolio?

Vanguard Small-Cap ETF(NYSEMKT:VB) provides a cost-efficient entry to small-cap stocks with high liquidity, while Schwab U.S. Small-Cap ETF(NYSEMKT:SCHA) offers broader diversification and has delivered higher recent total returns. Small-... Full story

Yahoo Finance • 20 days ago

US Stock Market Today S&P 500 Futures Flat As Traders Await Fed Decision

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. The Morning Bull - US Market Morning Update Wednesday, Apr, 29 202... Full story

Yahoo Finance • 21 days ago

Erasca Stock Sinks 48% in Race for Pancreatic Cancer Miracle Drug. What’s Behind the Sell-Off.

A confluence of safety concerns and underwhelming clinical data sent Erasca stock into a historic tailspin on Tuesday. Erasca late Monday reported positive Phase 1 trial results for ERAS-0015, a therapeutic drug candidate tailored to patie... Full story

Yahoo Finance • 21 days ago

Assessing Revolution Medicines (RVMD) Valuation After Positive RASolute 302 And Zoldonrasib Clinical Updates

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Clinical catalysts and pipeline momentum behind Revolution Medicines stock Revolution Medicines (RVMD) is in focus af... Full story

Yahoo Finance • 22 days ago

Revolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It Seems

If a stock has a market cap of nearly $30 billion, you would probably expect its business to be well developed, generating significant revenue, and likely profitable. But there's one stock trading at a valuation that not only isn't profita... Full story

Yahoo Finance • 25 days ago

SPSM Offers Lower Costs and Higher Yield Than ISCB

The State Street SPDR Portfolio S&P 600 Small Cap ETF(NYSEMKT:SPSM) carries a lower expense ratio and higher assets under management than the iShares Morningstar Small-Cap ETF(NYSEMKT:ISCB), while ISCB offers greater diversification by num... Full story

Yahoo Finance • 28 days ago

Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated clin... Full story

Yahoo Finance • 28 days ago

Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced preclinical... Full story

Yahoo Finance • 29 days ago

Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on

[Heart Health Concept] Eoneren/E+ via Getty Images As the market moves into the second week of Q1 earnings, we look at the most overbought stocks in the healthcare sector. Below is a list of the top 10 healthcare stocks ranked based on t... Full story

Yahoo Finance • last month

Revolution Medicines Prices $2 Bln Upsized Offering At $142/shr

(RTTNews) - Revolution Medicines, Inc. (RVMD), on Wednesday announced the pricing of its upsized concurrent public offerings totaling $2 billion, comprising stock and convertible senior notes. The company expects the offerings to close on... Full story

Yahoo Finance • last month

US Stock Market Today: S&P 500 Futures Edge Higher As Energy Inflation Jitters Linger

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. The Morning Bull - US Market Morning Update Tuesday, Apr, 14 2026 US stock futures are pointing slightly higher this morni... Full story